Nektar Therapeutics
NKTR
$75.06
$2.853.94%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -37.92% | 28.26% | 30.95% | 24.34% | 56.91% |
| Total Depreciation and Amortization | -76.63% | -79.55% | -69.36% | -54.92% | -43.81% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 84.62% | -211.57% | -27,163.24% | -1,209.17% | -157.44% |
| Change in Net Operating Assets | -493.30% | -6,578.32% | -262.79% | 101.14% | 68.71% |
| Cash from Operations | -18.67% | -7.46% | -5.81% | 6.21% | 8.77% |
| Capital Expenditure | 40.87% | 50.88% | -89.89% | -122.92% | -69.71% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -100.23% | -41.32% | 83.54% | 43.16% | 3.49% |
| Cash from Investing | -100.84% | -41.20% | 81.43% | 41.26% | 2.15% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 633.90% | 1,046.81% | 823.53% | 269.70% | 293.33% |
| Repurchase of Common Stock | -- | 100.00% | 100.00% | 100.00% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -102.56% | -102.56% | -100.00% | -100.00% | -- |
| Cash from Financing | 328.71% | 237.66% | -99.25% | -99.71% | 140,293.33% |
| Foreign Exchange rate Adjustments | 250.00% | 234.48% | 110.10% | -66.67% | -106.45% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -424.64% | 131.38% | 166.03% | 65.57% | 116.95% |